Business Wire

NY-IFF

25.6.2020 14:02:08 CEST | Business Wire | Press release

Share
IFF Embraces “Do More Good” in 2019 Sustainability Report

Regulatory News:

IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today published its 2019 Sustainability Report, “Do More Good.” The title references a pillar of the Company’s purpose, To redefine how we live in and care for the resources of our world , which was launched last year as part of its most significant rebrand in 40 years. The report highlights IFF’s sustainability accomplishments throughout the business and covers the Company’s achievements in leveraging sustainable practices within its global footprint.

Andreas Fibig, IFF Chairman and CEO, said: “The leadership position that we have taken in sustainability is a reflection of the passion to do more good that’s been embraced by our people everywhere at IFF. We credit our customers, partners and suppliers for the incredible and productive alliances we have forged together in the service of sustainability. This is not a journey we can – or want - to take alone. It requires the energy and commitment of like-minded allies willing to challenge the status quo – and each other – to do what is ultimately best for people and planet.”

The 2019 report highlights include:

  1. IFF’s new purpose and Vision 2021 strategy, reflecting the importance of sustainability as a way of doing business at IFF
  2. External recognitions for IFF’s sustainability leadership, such as Barron’s, FTSE4Good, RobecoSAM Industry Mover award, Euronext Vigeo, and CDP A list
  3. Continued commitment to climate action, as demonstrated by the opening of the Union Beach, New Jersey solar array, the signing of the U.N. Business Ambition for 1.5°C: Our Only Future pledge, and strong progress against its environmental goals for greenhouse gas emission reductions (including a decrease in absolute emissions of 5.7% from prior year), and zero waste to landfill and water stewardship
  4. Strengthening of IFF’s responsible sourcing program and natural ingredient supply chains through new certifications, as well as by accelerating industry-leading blockchain technology as a tool for ensuring ingredient traceability
  5. Achieving an industry breakthrough in circular design and transparency with Henry Rose, a line of fine fragrances founded by actress Michelle Pfeiffer and created to the strictest environmental standards as defined by the Environmental Working Group and the Cradle to Cradle Products Innovation Institute
  6. External recognitions and certifications for IFF’s diversity & inclusion leadership, such as DiversityInc., Human Rights Campaign, EDGE, and the signing of the U.N. Global LGBTI Standards of Conduct for Business and the U.N. Women’s Empowerment Principles
  7. Accelerated the inclusion of legacy Frutarom data, where available, in response to stakeholder interest and to prepare for the anticipated merger with DuPont’s Nutrition & Biosciences business. This process included a significant data collection and training effort for more than 60 facilities in 27 countries.

Dr. Greg Yep, IFF’s Chief Scientific & Sustainability Officer, said, “IFF’s sustainability accomplishments are considerable and meaningful and I must thank our global network of green teams who are empowered to drive change for IFF and our communities. As pleased as we are with our results, from external recognitions to meeting and exceeding our goals, I know I speak for all of IFF when I confirm our commitment to continually improve and drive better outcomes, and always seeks ways to live up to our purpose and do more good.”

To read IFF’s 2019 Sustainability Report, visit iff.com/sustain and use #SustainxIFF to follow the conversation on its social channels.

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye